更多栏目
搜索
China Licensing Deals Tracker: May 2021
储旻华·3月以前
PharmaDJ

Writer: Minhua Chu, Long Cheng

Editor: Justin Fischer


The volume of licensing deals in May this year has roughly kept pace with that of April, seeing 10 deals in total, seven of which were in-licensing agreements from overseas drug companies.


gaitubao_1 (3).png


Six deals disclosed their amounts, valued at a grand total $633 million, with an average of $105.5 million per deal.


gaitubao_2 (4).png


LianBio, a Chinese biotech company whose business model is sourcing first-in-class (FIC) therapeutic assets worldwide to China and other major Asian markets, inked two in-licensing deals. These were the highest and second highest valued of the six deals that were disclosed.


LianBio acquired two innovative autoimmune candidates from recently IPO-ed biotech Lando at the price of $218 million. The deal includes an upfront cash payment of $18 million, $200 million milestones, and future royalties.


The two oral gut-restricted small moleculars, Omilancor (BT-11) and NX-13, which target LANCL2 and NLRX1, repectively, are in late-stage development for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD) assets. The partners will bring them to China and other Asian markets, including South Korea, Singapore, Thailand, Vietnam, Myanmar, Cambodia, Indonesia and the Philippines.


The other deal is a cooperation with France-based late-stage clinical biotechnology company Nanobiotix to bring NBTXR3, a potential first-in-class radioenhancer for the treatment of tumors, to China and other Asian markets.


According to the terms of the agreement, Nanobiotix will receive a $20 million upfront payment, up to an aggregate of $220 million milestone payments, and tiered low double-digit royalties based on net sales of NBTXR3 in the licensed territories. LianBio will obtain exclusive rights to develop and commercialize the drug in Greater China, South Korea, Singapore, and Thailand.


Pregene Biopharma is a Shenzhen-based biotechnology firm that is developing innovative cell and gene therapy products. In May, it announced that it would sell the exclusive rights in India for PRG1801, an anti-BCMA CAR-T cell therapy injection to Dr. Reddy's Laboratories. The price of the sale was $12.5 million and includes double-digit royalties.  


gaitubao_WechatIMG5171.png
文章关键字: China Licensing Deals Tracker Pregene Biopharma Nanobiotix Crohn’s disease (CD) ulcerative colitis (UC) NX-13 LianBio Lando Omilancor(BT-11)
541
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明